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INTRODUCTION
The complement system, which consists of a group of proteins and
glycoproteins, generally serves to amplify the effects of the interaction of antigen
with antibody. In addition, this system, independent of immune mechanisms, can
initiate inflammatory responses and function as an important first line of defence.
Furthermore, complement plays a cardinal role in metabolising antigen-antibody
complexes. More recently, the immunomodulatory effects of several of its
components are also being studied.
It is currently held that the elimination of Mycobacterium leprae from the
humanhost is mainly through the T-lymphocytes and macrophages and that the
      complement system is not involved in this process. Nevertheless, in view of the
 active interaction of M. leprae with the complement system and the form&on of
         large amounts of immune complexes(IC) in leprosy, the importance of this system
in modulating certain immunopathogenetic phenomena is being recognized now. In
  this communication, the current state knowledge in this field will be reviewed
 and an attempt will be made to identify possible areas of future research where
lacunae exist.                                            
THE COMPLEMENT SYSTEM
This system bears certain resemblances to the coagulation system. Many
of the nearly 30 components which comprise this system exist as inactive
precursors or zymogens. More than one stimulus is capable of initiating the
activation of this system. Like the intrinsic and the extrinsic pathways of the
  coagulation system, complement can be activated via classical and alternative
pathways.
Components: The complement system comprises of three groups of
molecules. The first group consists of molecules directly involved in the
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activation. Since unchecked activation will lead to disastrous consequences to the
host, a number of control proteins form an essential part of this system. The
complement components and/or their activation products exert their effects on a
variety of cells through receptors present on their surfaces and these molecules are
known as complement receptors. Some of the features of the components and
complement receptors are shown in Tables I and II
Table I. Components of the complement system
Components involved in activation
Initial components
C1, C2, C4
Initiating factor, properdin,
- Classical pathway
- Altcrnativc pathway
factor D, factor B    
Amplificationcomponents                      
Cofactors and inhibitors
C4 binding protein, factor H          
C1 estcrase inhibitor, anaphylatoxin inactivator
C3b inactivator                           
Table II. Complement receptors
Ligand Receptor Present on   
C3a, C3aR Mast cells, monocytes,
C4a neutrophils, basophils, T cells
C3b, CR 1 RBCs, B and T cells monocytes.
i C 3 b ,  C 3 c  neutrophils,
C4b eosinophils
C3d, C3dg CR 2 B Cells, thymocytes,
iC3b dendritic cells
iC3b,C3d CR3 monocytes, neurophils, eosinophils,
dcndritic cells, R and NK cells.
iC3b CR4 Monocytes, neutrophils, K and NK cells.
C3dg,C3d CR 5 Neutrophils, platelets.
activators while other classes and subclasses seem to lack the ability to activate
the classical complement pathway. However, the alternative complement pathway
can be triggered by IC containing immunoglobulins of all classes. Here the critical
feature appears to be that the complex should be present in the form of a precipitate.
A variety of microbes including mycobacteria and a number of substances with
repeating subunit structures like polysaccharides are capable of initiating the
alternative pathway. Once triggered each component acts on the next component
and a sequential step-by-step activation takes place. This starts with C1 when the
classical pathway is activated and begins with the initiating factor in the case of
the alternative pathway. Both pathways have a common sequence from the level
of the third component till C9 which is the last component in the sequence. The
mechanism of activation is shown schematically in Fig.1.
Fig. 1. The classical and the alternative pathways of complement activtation.
Consequences: When the activation takes place on the surface of a cell,
multiple holes are formed and this leads to an osmotic lysis of the cell. In addition,
a number of other activation products are formed which exhibit a wide range of
420 
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biological effects. A summary of these is given in Table III.
Table III. Important biological effects of some of the active fragments of the complement
system
Fragment Biological action
C3a Anaphylatoxin, supression of immune response           - - - - - - - - - - - - - - - - - - - - - - - -
C4a Anaphylatoxin
- - - - - - - - - - - - - - - - - - - - - - - -
C4b Immune adherence- - - - - - - - - - - - - - - - - - - - - - - -
C3b Immune adherence, elimination of IC,
modulation of immune response
- - - - - - - - - - - - - - - - - - - - - - - -
C 3dg Modulation of immune response- - - - - - - - - - - - - - - - - - - - - - - -
C5a Anaphylatoxin, chemotaxis, enhancement of  
immune response
- - - - - - - - - - - - - - - - - - - - - - - -
C7,8,9 Membrane attack complex
Major functions: One of the earliest observed functions of the complement
system is that it is involved in the elimination of microbes. This is achieved by two
major mechanisms. The first is through opsonisation at the level of C3 which
facilitates the phagocytosis of micobes by neutrophils nad macrophages. The
phagocytes then kill the organisms through various microbicidal enzyme systems.
The second mechanism is lysis of the organisms with the aid of the membrane
attack complex (MAC) formed by the terminal components of the system.
The complement system promotes both acute and chronic inflammation
through its active fragments which have anaphylatoxic and chemotactic
properties. Further, activation of phagocytes and release of tissue - damaging
enzymes also add to the inflammatory potential of the system.
The important role of the complement system in metabolising IC is well
recognized now. This is achieved by prevention of immue precipitation through
the classical pathway, solubilization of precipitated IC through the alternative
pathway or by internalization of complement-reacted IC through the complement
receptors.
Complement components and their active fragments appear to function
as potent immuomodulators. The generation of B lymphocyte memory cells,
alteration of lymphocyte proliferation, stimulation of antibody production,
enhancement of antibody-dependent          cellular cytotoxicity are some of the
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documented effects of complement on the immune system (reviewed in Erdei et al
1991).
THE STATES OF THE COMPLEMENT SYSTEM IN LEPROSY
The involvement of the complement system in diseased individuals is
usually assessed by quantitating the blood levels of the components using
haemolytic or immunochemical methods. However, a major shortcoming in this
approach is the lack of dynamic information provided, and static profiles of
the complement system can be misleading. For example, normal levels of a
particular component, say C3 could be due to an increased synthesis which is
masked by an increased catabolism. Similarly, a decreased level could be either due
to lowered synthesis or due to an increased breakdown with normal synthesis.
The ideal way of assessing the complement system is by conducting
metabolic turnover studies of the various components. Unfortunately, this
is very time consuming and is beyond the reach of the average research worker
in leprosy. An alternative method which is advocated involves the quantitation
of the breakdown products of complement components (Perrin et al 1975). These
methods are based on the changes in physiochemical properties and expression
of new epitopes consequent to activation of the system. It is believed that a
combination of functional and immunochemical estimation using the above
mentioned principle is the best way of looking at the functioning of this system.
Although, there are a number of reports of complement profile in leprosy,
a vast majority of them give only static information and hence will not be discussed
any further. However, awareness of this problem has led investigators to use
more dynamic approaches.
Bjorvatn et al (1976) reported an increase in both C3d and inferred that
there is (a) activation of the complement system, especially during reactional states
and (b) a hypercatabolism of C3 with both increased production and breakdown.
Subsequently, Saha et l (1977;1983) noted an increase in the catabolic fragment
factor Ba during ENL reactions, While confirming the activation of this system
during the occurrence of ENL reactions, Ramanathanet al (1984) reported an
increase in C3d in patients with reversal reactions also.
As evidence of involvement of the complement system in leprosy,
especially during lepra reactions, mounted, efforts have been directed towards
establishing the temporal relationship between the activity of this system and
the evolution of reactions. Valentijn et al (1982), Saha et al (1982) and Ramanathan
et al (1991) have reported on sequential estimations of the levels of complement
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catabolic fragments before, during and following subsidence of lepra re ctions. It
is clear from these studies that the activation process continues and then declines
gradually only after the subsidence of reactions. A similar observation has been
made on the involvement of this system in reversal reactions also (Ramanathan
et al unpublished findings).
Since immunochemical estimations do not necessarily differentiate the
functionally active from inactive molecules, haemolytic assays have been
performed by a number of workers (Petchclai et al 1973; Bjorvatn et al 1976;
Valentijn et al 1982; Ramanathan et al 1986a). Haemolytic function of this system
appears to be intact and most of the investigators found near normal to
moderately elevated levels. Apart from the haemolytic function, the ability of
complement to solubilize IC has been studied extensively and this is discussed
in the section dealing with the role of complement in IC metabolism.
In addition to the foregoing, limited studies of the genetic polymorpisms
of C3 (Srivastava et al 1975), and C2, C4 and factorB (Grener et al 1980) have a
been performed. There were no discernible associations between the polymorphic
variants and the disease types or its manifestations in the cases of C2, C3 and factor
B. There was, however, a variant of C4 (called C4 F1) found only in a group of
BL and LL cases in the study. It must be stated here that more detailed analyses
of the polymorphic variants need to be done using currently available molecular
biology tools such as restriction fragment length polymorphism (RFLP). the
findings thus obtained must then be correlated with theclinical features of leprosy.
THE lNTERACTION OF MYCOBACTERIA WITH THE COMPLEMENT SYSTEM
Activation by whole organism: In 1959, Heyman and Wahlig showed that
M.tuberculosis could activate thealternative pathway of the complement a system
(AX). After a gap of nearly two decades, Kondo and his colleagues (1978)
found that BCG was capable of triggering the APC. The APC activating potential
of M.leprae was first demonstrated by Ramanathan et al (1980) and subsequently
by others (Saha et al 1983; Schlesinger & Horwitz 1990a). It is known that a
number of other mycobacteria apart from M.leprae, M.tuberculosis and BCG can
also activate the APC (Parkash et al 1987).
Activation by components: In addition to the whole organism, various
components of mycobacteria can also trigger the system. Rourke et al (1979) found
that purified protein derivative (PPD) even in the absence of antibody bound C1
activated the complement system, and cord factor or trehalose dimycolate from
M.tuberculosis could activate the APC.
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Recently, it has been shown that phenolic glycolipid 1 (PGL) of M.leprae
is capable of activating the complement system (Ramanathan et al 1990;
Schlesinger & Horwitz, 1990b). It is interesting to note that unlike PPD or cord
factor which activate only one pathway, PGL seems to act on both the pathways.
Furthermore, the active moieties are found in the sugar as well as the lipid
components.
The effect of antibody on the activation by mycobacteria: Although the
activation of APC can take place under antibody free conditions,investigations
done in the last decade reveal that antibodies can augment the activation through
the APC (Ratnoff et al 1983). Thus, the addition of antibodies against rabbit
erythrocytes, zymosan, bacteria such as Escherichia coli, neisseria, salmonella
and viruses like the influenza virus potentiated their activating ability. Further,
it has been found that unlike the classical pathway, the Fc portion of the
immunoglobulin molecule is not critical for the APC amplifying effect.
The activation of complement by mycobacteria and their components
takes place in vitro under antibody free conditions. However, since antibodies to
mycobacteria are produced in diseased individuals, the effect of these on the
activation has also been studied recently.Chakrabarty and Saha (1986), found
that the addition of heat inactivated serum from active lepromatous leprosy
patients but not healthyvolunteers, increased the activation of complement by
M.leprae. Subsequently, Parkash et al (1988) demonstrated an increase in APC
activation when BCG and M.vaccae were precoated with antibody. Similarly, IgM
class of antibodies were shown to augment the classical pathway activation of
PGL while IgG class of antibodies were responsible for the increase in APC
activation (Ramanathan et al1990).
Consequences of activation to the organism: In the case of many microbes,
activation of complement results in the lysis of the organisms. Since mycobacteria
appear to be potent activators of the complement system, experiments were
conducted to determine whether activation is followed by the destruction of the
bacilli. Parkash and his colleagues (manuscript under preparation) found that BCG
and M.vaccae did not lose their viability after reacting with human complement.
Similarly, in view of the activation augmenting ability of antibody, immunoglobulins
against BCG and M.vaccae were added before being treated with complement,
However, it was found that this also did not result in the killing of the bacteria
although addition of antibody increased C3 uptakeby these bacteria. This was
further confirmed whenultrastructural studies revealedthat there were no
differences between  complement-reacted and the control bacilli.Although such
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studies have not been made using M.leprae, it is reasonably safe to assume that
this organism also will be similar to BCG and M.v ccae in its behaviour.
One major reason for the ineffectiveness of complement-mediated killing
could be the tough cell wall of this group of organisms.In addition, these bacteria
may employ other strategies also to evade the lyric effect of complement For
example, sialic acid present in the capsule of many organisms prevents the
deposition of C3b. Further mechanisms involved are microbial shedding of
molecules thatdestroy complement, synthesis or aquisition of regulatory
molecules, blockade of activation of complement before the formation of the
terminal attack complex (C5b-9) and formation of a nonlytic C5b-9 complex
(reviewed in Joiner 1988). It is not known whether mycobacteria, especially the
pathogenic ones use any of these above mentioned mechanisms to escape
complement-mediated lysis.
Currently available information indicates one mechanism employed
M.leprae as a survival strategy. It is known that opsonisation of bacteria by
complement C3b leads to phagocytosis. Although this usually aids the host to get
rid of the invading organism, intracellular parasites may utilise this very property
for their existence in an otherwise hostile environment Recently, Schlesinger
and Horwitz (1990a) have shown that monocytes phagocytose complement-
reacted M.leprae through CR1 and CR3. It is possible that this phenomenon of
phagocytosis is likely to aid the host whose immune mechanisms are capable of
killing the bacilli. On the other hand, phagocytosis probably assists theorganism
to Survive in the individual who is susceptible to get the disease.
ACTIVATION OF THE COMPLEMENT SYSTEM IN LEPROSY
As discussed earlier, there is evidence to suggest that there is a marked
degree of activation of the complement system in leprosy. A number of
mechanisms seem to be operative in initiating this important phlogistic system.
A major contribution towards this activation is made by M.leprae and PGL 1. It-
is likely that cytoplasmic components of M.leprae are also capable of activating
the system as has been found with BCG and M.vaccae (Parkash et al unpublished
observations).
High levels of immune complexes (IC) have been demonstrated by several
workers to occur throughout the spectrum of leprosy. It is well known that IC are
potent activators of the complement system. Saha et al (1984) and Tyagi and her
coworkers (1990) demonstrated that circulating IC from leprosy patients could
activate complement.
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It is known that many lysosomal enzymes such as beta glucuronidase,
aryl sulfatase, acid phosphatase and cathepsin are elevated in leprosy (Palekar &
Magar 1967; Venkatesan et al 1979). Schorlemmer and Allison (1976) found that
many of the acid hydrolases and other enzymes released by macrophages on
activation are capable of cleaving C3 and C5 generating a number of nascent
products by a process of proteolysis. It is thereforeconceivable that lysosomal
enzymes also contribute to the activation of the complement system both locally
and systemically in leprosy.
COMPLEMENT - MEDIATED INFLAMMATION IN LEPROSY
Complement activation in the leprosy patients by any of the above mechanisms
results in the generation of a number ofnascent molecules. A major consequence
of this activation appears to be the development of both acute and chronic
inflammation.
Acute inflammation: Reactions that occur in leprosy represent acute
episodes superimposed on the underlying chronic state. Of the two major types
ofreactions that are recognized it isbelieved that Type I or the reversal reaction
is due to an increase in the delayed hypersensitivity component of the T cell limb
of the immune system. On the otherhand, Type II or the erythema nodosum
leprosum (ENL) syndrome is considered to be mediated through the immune
complexcomplement axis.
As discussed earlier, several groups of workers have demonstrated a
state of hypercatabolism of the complement system during ENL reactions. A
sequential study of complement levels by Ramanathan et l (1991) indicatesthat
the catebolic fragment C3d is elevated at two time points in the disease process.
The first is when the patient is yet to be treated and the second is during ENL
reactions.
Activation of complement  in the untreated state is probably due to the high
levels of M.leprae and IC. This activation, however, is not always accompanied
by overt signs of acute inflammation and may be related to the induction of a
chronic granulomatous response.
The presence in the serum of complement breakdown products such as C3d
and factor Ba during reactional states represents activation of the system at the
sites of acute inflammation. The probable sequence of induction of acute
inflammation can be partly deduced from currently available information. Since
ENL occurs usually after starting treatment, it is believed that bacillary products
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that are released from M.leprae complexed with their corresponding antibodies
precipitate at various sites like the skin, joints, uveal tract and glomeruli The
precipitated complexes then activate the complement system which results in the
generation of molecules with anaphylatoxic and chemotactic properties.
Anaphylatoxins, by virtue of their smooth muscle contracting ability, increase
the local vascular permeability and produce oedema while chemotactic factors
attract neutrophils into the affected site. The neutrophils then release some more
tissue damaging enzymes as a result of stimulation by both IC and complement.
component C3b. Thus, the presence of neutrophils, IC and complement as well as
oedema and erythema at the sites of ENL reaction can be explained.
A decrease in theconcentration of complement catabolic fragments following
the subsidence of ENL reaction and the control of these reactions by drugs such as
corticosteroids and chloroquine which have potent complement inhibiting properties
indicate the important role played by the complement system in the genesis of
this type of reactions.
Although it is widely believed that reversal reactions are due to increased
delayed hypersens itivity, evidence suggestive of involvement of complement in
this phenomenon also, is now available.Ramanathan et al (1984, 1986) reported
an increase in the levels of C3d and a decrease in the amount of complement
mediated IC solubilization in patients undergoing reversal reactions. A number
of investigators are of the view that an increase in delayed hypersensitivity is
responsible for the production of these reactions. It is likely that theconcomitant
activation of macrophages locally leads to the release of proteases which then
generate nascent complement products. Therefore, this system probably
supplements thedelayed hypersensitivity induced inflammatory processes in
reversal reactions.
Chronic granulomatous inflammation: A ce tral role for the production
of chronic granulomatous inflammation by the complement system was proposed
by Schorlemmer and his coworkers (1977). This model was formed on the basis
of two major findings: (i) The ability of agents which induce granulomatous
inflamation to activate the complement system on the one hand and to stimulate
the macrophages to release lysosomal hydrolases and complement components
locally, and (ii) the property of lysosomal enzymes to cleave C3 and C5 generating
active products.
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thegeneration of inflammation and the production of C5a which acts as a
chemoattractant drawing initially neutrophils and later monocytes (which mature
into macrophages) into the site. Before the onset of specific immune processes
which kill the bacilli or in the individual who is not capable of producing a
bactericidal response, the bacteria persist interacellularly in the macrophages
stimulating them to release both lysosomal enzymes and complement components
such as C3 and C5. The enzymes activate C5 to form C5a and C5b. Since C5a is a
potent chemotactic factor for monocytes, recruitment of fresh macrophages takes
place, gradually building up a collection of macrophages resulting in a granuloma.
This is the initial attempt of the host in an immune individual and the main
mechanism in a susceptible person to physically limit the spread of organisms
further.
In subjects who mount an adequate immune response to M.leprae,the
granuloma resolves when the bacilli are eliminated. On the other hand, when the
immunity is only partially adequate, such as in those who develop the
paucibacillary forms of the disease, the granuloma is maintained by other
mechanisms, especially those involving T cell responses.
A further means of perpetuating thechronic granulomatous inflammation
initiated through complement activation is provided by antigen-antibody
complexes which occur in patients through the spectrum of leprosy. This is based
on the finding that IC are potent activators of both complement and macrophages.
  Further, it has been shown experimentally, that IC are capable of inducing a
granulomatous response involving antigen antibody systems of non-mycobacterial
and mycobacterial antigens (Spector & Heesom 1969; Ridley et al1982).
THE ROLE OF COMPLEMENT IN IC METABOLISM IN LEPROSY
It is now recognised that the complement system plays a pivotal role in
containing and eliminating IC from the body. This appears to be mediated through
three major mechanisms which are: (i) prevention of immu e precipitation, (ii)
solubilization of precipitated IC and (iii) elimination of IC mediated through
complement receptors.
Prevention of immune precipitation: First described by Schifferli and
his co-workers (1980), this function of the complement system is mediated by
components belonging to the classical pathway which prevent the aggregation and
precipitation of IC that have reacted with the first component C1. Although this
appears to be an important mechanism, there are no published reports of the status
of this function of the complement                         system in leprosy.
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Solubilization of precipitated IC: A new function of the complement
system was described by Miller and Nussenzweig in 1975. They found that when
precipitates of antigen-antibody complexes reacted with a large excess of
complement, they were broken down into smaller aggregates and lost their ability
to activatecomplement further and to bind to cellular receptors. This function is
mediated essentially by components of the alternative pathway, though C2 and
C4 of the classical pathway also contribute substantially. A depression of
complement - mediated solubilization (CMS) has been reported in many diseases
where IC appears to play a pathogenic role (Schifferli et al 1981; Baatrup et al
1983).
Ramanathan et al (1986a) reported that CMS was reduced in patients
undergoing reactions of both types but not in patients who did not suffer from
reactions. Subsequently, Chakrabarty and his coworkers (1988) also noted a
similar decreasein the levels of CMS in leprosy patients. However, they did not
find any difference between the reactional and non-reactional patients. A
prospective study of untreated multibacillary leprosy patients in whom sequential
estimations of CMS were performed revealed that there was a reduction in CMS
levels well before the onset of reactions which persisted long after their subsidence
also. This did not correlate with either C3d or immunoglobulins (both free and
complexed) titres (Ramanathan e  al 1991).
The possible involvement of the complement system in the production
of reversal reaction was discussed in an earlier section. Ramanathan et 1 (1986a)
and Chakrabarty et al (1988) found that BT patients with reaction had much lower
CMS levels than non-reactional BT patients. A sequential study of CMS, similar
to the one reported in LL patients (Ramanathanet al 1991) was undertaken by us
in BT patients. Here again, we found that reactional patients exhibited markedly
lower CMS levels than those who did not develop reactions at all during a four
year clinical followup (manuscript under preparation). In these cases also, the
  depressed CMS persisted even after the clearance of the disease and it did not
correlate with circulating IC or C3d levels.
In brief, studies on complement-mediated IC solubilization reveal that
(i) the reduction in the levels of CMS is essentially confined to patients prone
to getting lepra reactions of both Type I and Type II, (ii) the reduction persists for
long periods even after the susbsidence of reaction and in BT patients even after
the disease itself becomes inactive, (ii) the lower levels of CMS contrast with the
near normal or slightly elevated haemolytic complement levels and (iv). the levels
do nor correlate with circulating IC or C3d concentrations.
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In view of the selective depression of CMS in reactional patients and since
solubilized or partially solubilized IC are known to be potent immunomodulators,
a hypothesis can be proposed with the defective CMS as a predisposing factor for
reactions (Ramanathan et al 1986b).
The inability to inactivate and dispose of the IC that are formed during the
course of the disease effectively, results in the modulation of the immune system.
Thus, in BT patients, this may lead to stimulation of T cells mediating delayed
hypersensitivity; and in LL patients, this results in the activation of B cells
leading to an increase in the immunoglobulin levels along with the formation
of antigen-reactive T cells. The latter effect may be responsible for shedding of
more antigens from M.leprae eventually producing more IC, thereby setting up a
self-perpetuating cycle. Further, unsolubilized IC by themselves will activate
macrophages, complement and other phlogistic systems resulting in an inflammatory
process. Thus, IC could initiate inflammation in both types of lepra reaction.
While, it is likely that this inflammation is mediated through delayed hypersensitivity
associated mechanisms in Type I reaction, IC may play an additional role
of mediating the inflammatory process in the ENL syndrome. This hypothesis is
shown schematically in Fig 2.
No reactions
Stimulation of
Celluar
Hypersensitivity
Stimulation of
Macrophages
Enzyme release
Stimulation of Ab
production
Ag-Ab complex
formation due to
Ag release by T
cell activation
Indian J Lepr Vol.63(3,4) 1991 
Eliminationof IC through complement receptors: A hi d mechanism
which is recognised to eliminate IC using the complement system is through
complement receptors(CR). Of the various CRs, CR1 has been extensively
studied in individuals suffering from ICediated phenomena and it has been
suggested that there is a reduction in the number of CR1 in such patients.
To date, there has been only one reported study of complement receptors
in leprosy (Tausk et al 1985). These authors noted a significant decrease in the
number of CR1 present onthe red blood cells of patients with lepromatous leprosy
but not in those with paucibacillary disease. It is argued by these workers that the
reduction in CR1 could be due to receptor occupancy by circulating IC. Clearly,
further studies of these receptors are needed to evaluate their status and their role
in various forms of leprosy and their relationship to such complications as
reaction.
CONCLUS IONS
From the foregoing, the following are apparent: (i) There is a hypercatabolism
of the complement system in leprosy along with a reduction in the solubilization
of IC through complement; (ii) M.leprae and its constituents can activate the
complement system; and (iii) The complement system gets activated in leprosy
by more than one stimulus. This can result in the generation of both acute and
chronic inflammatory processes. Phagocytosis of complement -reacted M.lepra
early in the course of the disease is of advantage to the host who is capable of
initiating bactericidal mechanisms. On the other hand, this helps the organism
to gain entry into an immunologically privileged site in a susceptible host.
Although a considerable amount of information regarding the
pathophysiology of the complement system in leprosy is available now, there are
still several areas of theoretical and practical importance to be covered in this field.
The present review concludes with some of the lines of enquiry which need to
be pursued in the next decade: (i) Apart from its thick cell wall, does M.leprae
get protected from the effects of complement in influencing the course of events
in the early stages of host-parasite interaction? (ii) What is the role of complement
in influencing site course of events in the early stages of host- parasite
interaction? (iii) What is the reason for the dichotomy between the haemalytic
function and the ability to solubilize IC? Are different polymorphic forms,
especially those belongingto the class III products of the major
histocompatibility region responsible for           the  schism between two f the functions
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